As of today, people can make bookings to receive the NOVAVAX COVID vaccine. Why is that a big deal? Well, it’s a bit different from existing COVID jabs, and there’s hope it might get some of the vaccine holdouts over the line.

University of Queensland Infectious diseases physician and clinical microbiologist, Professor Paul Griffin was a local lead clinical trial investigator during the phase 1 and 2 studies of the Novavax vaccine. He joins Ben to explain what it is, and why it could get the last of the vaccine hesitant over the line.

As of today, people can make bookings to receive the NOVAVAX COVID vaccine. Why is that a big deal? Well, it&rsquo;s a bit different from existing COVID jabs, and there&rsquo;s hope it might get some of the vaccine holdouts over the line.
University of Queensland Infectious diseases physician and clinical microbiologist, Professor Paul Griffin was a local lead clinical trial investigator during the phase 1 and 2 studies of the Novavax vaccine. He joins Ben to explain what it is, and why it could get the last of the vaccine hesitant over the line.

If you enjoyed listening to The West Live for your daily news fix, then come and join us over on The Nightly Five.  Host Ben O’Shea continues to deliver punchy news and analysis, in a new podcast to get you in front of tomorrow’s news today!  Subscribe on your favourite podcast player and visit the thenightly.com.au

If you enjoyed listening to The West Live for your daily news fix, then come and join us over on The Nightly Five.  Host Ben O’Shea continues to deliver punchy news and analysis, in a new podcast to get you in front of tomorrow’s news today!  Subscribe on your favourite podcast player and visit the <a href="https://thenightly.com.au">thenightly.com.au</a>

Advertisement